Drug intelligence / Profile preview

LDN-0712

Development stage: Preclinical
Lead developer: Ladon Therapeutics
Modality: Peptides, Small Molecules
Administration: Oral

Overview

LDN-0712 is a first-in-class, dual-acting oral peptide mimic being developed by Ladon Therapeutics for the treatment of fibrosis and various inflammatory diseases. It functions by modulating A3SMO, a target identified by Ladon's proprietary platform to address the underlying drivers of fibro-inflammatory pathology. Currently in the preclinical stage, LDN-0712 is designed for oral administration to provide a more convenient therapeutic option compared to injectable biologics, aiming to reduce both tissue scarring and the associated inflammatory response.

Beyond the preview

Go deeper on LDN-0712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDN-0712.

Explore the full profile